[January 14, 2013]

Research and Markets: Demyelinating Diseases - Pipeline Review, H2 2012

Research and Markets (http://www.researchandmarkets.com/research/qtg6n4/demyelinating) has announced the addition of Global Markets Direct's new report "Demyelinating Diseases - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Demyelinating Diseases - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Demyelinating Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Demyelinating Diseases.

Scope

- A snapshot of the global therapeutic scenario for Demyelinating Diseases.

- A review of the Demyelinating Disases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Demyelinating Diseases pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- News and deals relating to the products.

Reasons to Buy

- Identify and understand important and diverse types of therapeutics under development for Demyelinating Diseases.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Demyelinating Diseases pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/qtg6n4/demyelinating

Source (News - Alert): Global Markets Direct

[ Back To Technology News's Homepage ]